Lakefront Biotherapeutics (LKFT) Net Cash Flow (2015 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Net Cash Flow for 12 consecutive years, with -$38.3 million the latest figure, recorded in Q1 2026.

• Quarterly Net Cash Flow fell 182.52% year-over-year to -$38.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$44.9 million (down 588.58% YoY) and the FY2025 annual result came in at -$25.4 million, up 88.91% from the prior year.
• Net Cash Flow declined to -$38.3 million in Q1 2026 per LKFT's latest filing, from -$4.6 million in the prior quarter.
• Over the last five years, Net Cash Flow for LKFT reached as high as $46.4 million in Q1 2025 and fell as low as -$1.1 billion in Q1 2022.
• A 5-year average of -$149.5 million and a median of -$29.1 million in 2023 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow slumped 208352.51% — and 2025, when it soared 138.36%.
• Year by year, Net Cash Flow stood at -$186.2 million in 2022, then surged by 84.36% to -$29.1 million in 2023, then fell by 19.18% to -$34.7 million in 2024, then soared by 86.86% to -$4.6 million in 2025, then plunged by 738.53% to -$38.3 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$38.3 million, -$4.6 million, and -$1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.